GenLight Medical

About GenLight Medical

GenLight Medical, also known as Genlight Neurotech, is a data-driven, full-stack brain-computer interface (BCI) platform company founded in 2020 by CEO Cao Peng. Headquartered in Hangzhou, China, with an international center in Singapore, the firm focuses on the precision diagnosis and treatment of brain disorders, closed-loop neuromodulation, and brain health management. GenLight has successfully secured several hundred million yuan through consecutive Series C and D financing rounds to advance its product commercialization and international expansion. The Series C round was led by Qiming Venture Partners, while the D round included backing from Saizhi Bole, Kuanqiao Hengsong, and Ningbo state capital. The company develops and commercializes implantable neurostimulation technology and supporting systems. Its product portfolio includes the Epilcure™ system, an implantable BCI neurostimulator designed to treat drug-resistant focal epilepsy. This device monitors intracranial EEG activity and delivers responsive stimulation to counteract abnormal signals. Another core product is the Vivastep™ spinal interface, which has shown promise in aiding motor function recovery in patients with spinal cord injuries. Additionally, GenLight has commercialized its LaserRO™ magnetic resonance-monitored laser ablation system and S-Deep™ intracranial depth electrodes, both of which have received Class III medical device registration in China. These products work in synergy for precise lesion treatment and signal localization, supporting the company's broader BCI platforms. GenLight operates a business model centered on a “neural interface – data – AI model – closed-loop modulation” technology path. This allows the company to build a reusable technology foundation for various diseases and neuromodulation scenarios. Its revenue is driven by the sale of these advanced medical devices. The company has established a clinical collaboration network with over 50 top-tier hospitals in China for multicenter studies and product applications. GenLight holds an extensive intellectual property portfolio with over 400 applications and more than 190 authorized patents. The company is actively pursuing regulatory approvals from the United States FDA and European CE to enter international markets.